Indications › Substance use
GLP‑1 drugs in substance use
Which incretin agents are being studied in substance use, by whom, and when each trial is due to report. Conditions are grouped from the registry’s own wording, which records the same disease several ways.
- Trials on file
- 22
- Active
- 16
- Results scheduled
- 5
- Molecules studied
- 5
- Sponsors
- 17
No GLP‑1 or incretin drug is FDA-approved for substance use. The trials below are studies, not approvals, and most drugs tested in a new condition never get approved for it.
No GLP-1 or incretin drug is approved for substance use, so everything below is investigational. Most drugs tested in a new condition never reach approval for it, and a registration is not evidence of benefit. 2 of the 22 trials on file are phase 3 or later — the stage sized for a regulator to act on, against 20 still in early phases. 17 distinct sponsors are involved.
Molecules studied in this indication
dulaglutide · exenatide · liraglutide · semaglutide in this indication · tirzepatide
Results due in this indication
| Est. completion | Drug | Trial | Phase | Participants |
|---|---|---|---|---|
| 2027-04-30 | semaglutide | GLP-1R Agonist Treatment for Opioid Use Disorder NCT06548490 · Milton S. Hershey Medical Center | P2 | 200 |
| 2027-09-30 | tirzepatide | Evaluation of Tirzepatide as an Adjunct to Buprenorphine for the Treatment of Opioid Use Disorder NCT06651177 · T. John Winhusen, PhD | P2 | 310 |
| 2028-03 | tirzepatide | Multi-Site Trial of Tirzepatide for Smoking Cessation NCT07602699 · University of Southern California | P2 | 300 |
| 2028-03-15 | tirzepatide | Trial of Tirzepatide for the Treatment of Cannabis Use Disorder NCT07468552 · National Institute on Drug Abuse (NIDA) | P2 | 100 |
| 2028-04-30 | semaglutide | Effect of Semaglutide on Cannabis Use in Adults With Cannabis Use Disorder NCT07523633 · Anders Fink-Jensen, MD, DMSci | P2 | 100 |
Trials on file
All 22 incretin trials recorded in this indication, active first.